PDA

View Full Version : Communication to the Shareholders Ranbaxy Laboratories Limited


megri
02-25-2014, 05:38 AM
Ranbaxy Laboratories Limited
Regd. Office : A-41, Industrial Area Phase VIII-A, Sahibzada Ajit Singh Nagar, Mohali-160071 (Punjab)



Dear Shareholder,

Subsequent to my communication on January 27, 2014 on the developments regarding our Toansa Active Pharmaceutical Ingredients (API) plant, I take this opportunity to give you a further update.

We are currently examining processes and controls at all our API Manufacturing and Quality units. This action has led to temporarily putting on hold shipments from our API facilities of the Toansa and Dewas plants.

This voluntary decision was taken as a precautionary measure and out of abundant caution to better allow us to assess and review the processes and controls. We will resume shipments after reassuring ourselves about the processes and controls at these facilities.

In the meanwhile, a committee of the Board has been constituted in Feb 2014 as the "Quality & Integrity Committee". The Committee's objective is to help and assure good governance to all Ranbaxy stakeholders. Its primary role is to provide oversight on the Company's manufacturing and quality operations, systems, organization and integrity.

We recognize that trust is fundamental to our relationship with all our stakeholders. I would like to assure you that the necessary corrective actions to improve our systems and processes are the critical steps towards upholding the trust our stakeholders have in Ranbaxy. While we maintain confidence in the quality of all our products, we will do everything we can to ensure that Ranbaxy emerges as an even stronger, trusted and respected company as we go through these challenging times.

I will keep you updated on further development.

Thank you for your unstinted support.

With Best Regards,

Arun Sawhney
CEO & Managing Director

Our Philosophy: Quality and Patients First
(i) The information contained in this e-mail message is intended only for the confidential use of the recipient(s) named above. This message is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail, and delete the original message. #Ranbaxy$2013=* (ii) The sender confirms that Ranbaxy shall not be responsible if this email message is used for any indecent, unsolicited or illegal purposes, which are in violation of any existing laws and the same shall solely be the responsibility of the sender and that Ranbaxy shall at all times be indemnified of any civil and/ or criminal liabilities or consequences there.